Key clinical point: Dupilumab may be more effective in reducing severe asthma exacerbations in patients with late-onset asthma than in those with early-onset asthma, but the drug’s effect on lung function appears the same regardless of onset.
Major finding: In late-onset patients, dupilumab reduced exacerbations by 64% at a 200-mg dose and 69% at a 300-mg dose (P less than .001 vs. placebo).
Study details: Subanalysis of a phase 3 trial including 919 patients with early-onset asthma who received dupilumab, 450 early-onset patients who received placebo, 345 patients with late-onset asthma who received dupilumab, and 188 late-onset patients who received placebo.
Disclosures: This research was sponsored by Sanofi and Regeneron. Dr. Hanania disclosed relationships with AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Regeneron, and Sanofi.
Hanania N et al. CHEST 2019. Abstract, doi: 10.1016/j.chest.2019.08.870.